RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and ...

People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...

Depression screening predicts subsequent disability progression in people with primary progressive multiple sclerosis.

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest independent research center focused on multiple sclerosis, has published groundbreaking new research ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

Three investigators and their teams have received funding for clinical trial development projects as part of the International Progressive MS Alliance’s Experimental Medicine Trial Awards. These ...

Share on Pinterest Stem cell therapy could help halt the progression of cognitive impairment in multiple sclerosis. Image credit: TEK IMAGE/SCIENCE PHOTO LIBRARY/Getty Images. About 2.8 million people ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Scientists have uncovered two closely related cytokines -- molecules involved in cell communication and movement -- that may explain why some people develop progressive multiple sclerosis (MS), the ...